Introduction {#Sec1}
============

The prevalence of diabetes is increasing worldwide. In Italy, 3.18 million people aged 15 years and over were estimated to be suffering from diabetes in 2016 (6.1% of the population for this age group) \[[@CR1]\]. Type 1 diabetes (T1DM) and type 2 diabetes (T2DM) represent 5.4 and 91.9% of all diabetes cases in Italy, respectively, with the remaining 2.7% of cases made up of secondary diabetes (2.1%) and 'other' types (0.5%) \[[@CR2]\].

Hypoglycemia, a common adverse effect of insulin therapy, is defined by the American Diabetes Association as blood glucose levels below an alert value of 70 mg/dL (with clinically significant hypoglycemia defined as a blood glucose level of \< 54 mg/dL) \[[@CR3]\]. Hypoglycemia is defined as non-severe when the episode can be self-treated with glucose or a sweet drink or snack (15 g oral glucose according to Italian treatment guidelines for diabetes) \[[@CR4]\]. Severe hypoglycemia requires third-party assistance and treatment with oral or intravenous glucose or intramuscular/subcutaneous injections of glucagon \[[@CR4]\]. A severe episode may be treated by family or friends at home or work or may require assistance from emergency healthcare professionals (HCPs), in which case an ambulance, accident and emergency (A&E) department and hospital treatment may be required. The Associazione Medici Diabetologi and Società Italiana di Diabetologia recommend self-monitoring of blood glucose (SMBG) testing every 15 min after the onset of hypoglycemia until at least two normal values are measured in the absence of further treatment between the two measurements \[[@CR4]\]. Patients may also consult their general practitioner (GP) or a diabetes specialist after a severe or non-severe hypoglycemic episode.

Hypoglycemia therefore represents a substantial economic burden to healthcare systems, with costs ranging from a few Euros for a non-severe episode, to very high costs for a severe episode requiring hospitalization of the patient \[[@CR5]\]. Due to greater event frequency, the treatment of non-severe hypoglycemia may incur similar or greater annual costs than that of severe hypoglycemia \[[@CR6], [@CR7]\]. The aim of this study was to estimate the cost of insulin-related hypoglycemia in Italy using the Local Impact of Hypoglycemia Tool (LIHT), a model used previously for analyses in the UK \[[@CR5]\], Denmark \[[@CR6]\] and Spain \[[@CR7]\]. In the current analysis we also explore the potential variation in budget impact arising from different hypoglycemia rates.

Methods {#Sec2}
=======

The LIHT was developed for the UK and the methods have previously been described \[[@CR5]\]. Briefly, the cost and utilization of specific healthcare resources are applied to a population of adults with T1DM and T2DM and their corresponding severe and non-severe hypoglycemia episode rates. In the current analysis, the LIHT was used to estimate the cost of hypoglycemia in Italy and the potential cost savings from a reduction in severe and non-severe hypoglycemia rates.

Patients and Hypoglycemia Rates {#Sec3}
-------------------------------

The population of Italy, number of adults, and number of adults with diabetes were obtained from Italian National Institute of Statistics (ISTAT) data for 2016 \[[@CR1], [@CR8], [@CR9]\]. At that time the total population of Italy was estimated to be 60,579,000, with 86.3% aged ≥ 15 years. Of those aged ≥ 15 years, 3,182,000 people suffered from diabetes, corresponding to a prevalence of 6.1%.

All patients with T1DM (171,828) were assumed to be treated with insulin in this analysis. For patients with T2DM, the HYPOS-1 study, an Italian, questionnaire-based, retrospective study \[[@CR10]\], was used to inform the proportion of insulin-treated patients. In HYPOS-1, 30.1% of patients with T2DM were reported to be treated with insulin (15.1% with oral antidiabetic drugs \[OADs\] plus insulin and 15.0% with insulin alone); the remaining patients were treated with OADs (59.9%) and lifestyle intervention (10.0%). Therefore, 880,202 patients with T2DM were assumed to be treated with insulin in the current analysis (Table [1](#Tab1){ref-type="table"}).Table 1Population in the modelPopulationNumber of peopleTotal Italian population60,579,000Adult Italian population (aged ≥ 15 years)52,279,677Adult Italian population with diabetes3,182,000 T1DM (5.4% of diabetic population; all assumed to be insulin-treated)171,828 T2DM (91.9% of diabetic population)2,924,258  T2DM treated with insulin (30.1% of T2DM population)880,202*T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus

Hypoglycemia rates were also taken from HYPOS-1; patients with T1DM were reported to experience an average of 0.49 severe and 53.3 non-severe episodes per year \[[@CR11], [@CR12]\], while patients with T2DM experienced an average of 0.09 severe and 9.3 non-severe episodes per year \[[@CR10], [@CR12]\]. In line with Italian guidelines, severe hypoglycemia in the HYPOS-1 study was defined as an episode of hypoglycemia that led to unconsciousness or required intervention of a third person. Non-severe episodes were defined as the onset of one or more of the following symptoms, which resolved with the ingestion of food or a sugary drink: palpitations, tremors, sweating, difficulty concentrating, dizziness, hunger, blurred vision, confusion, or difficulty moving \[[@CR10], [@CR11]\].

Resource Utilization {#Sec4}
--------------------

The HYPOS-1 study informed utilization values for ambulance, A&E, hospitalization, diabetes specialist visits, and GP visits \[[@CR10]--[@CR12]\]. As no data were identified on the percentages of severe episodes treated in different settings in Italy, these values were taken from a survey of people with diabetes in Germany, Spain, and the UK \[[@CR13]\]. A weighted average across the three countries found that HCPs treated 33.3 and 43.2% of severe episodes experienced by people with T1DM and T2DM, respectively. For severe episodes treated by HCPs, it was assumed that the cost of glucose and/or glucagon was included in the ambulance, A&E or hospitalization tariff to avoid double counting. Due to a lack of available utilization data, the cost of glucose and/or glucagon was assumed to be zero for severe episodes treated at work/home, and for non-severe episodes.

Patients use extra SMBG tests following a hypoglycemic episode to monitor their blood glucose more closely until it is stabilized. There was a lack of data for Italy on the number of extra SMBG tests used, so this information was taken from a survey-based study of 1404 patients with diabetes in the US, the UK, Germany, and France \[[@CR14]\]. It was found that, on average, patients use 5.6 extra SMBG tests in the week following a non-severe episode. As no equivalent data were identified for severe episodes, the value for non-severe episodes was assumed to also apply to severe episodes. This is a conservative assumption, since patients are likely to monitor their blood glucose levels more closely following a severe episode than following a non-severe episode. The treatment pathway and resource utilization values applied in the model are shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Treatment pathway and resource utilization. *A&E* accident and emergency, *GP* general practitioner, *HCP* healthcare professional, *SMBG* self-monitoring of blood glucose, *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus. Dagger (†) Patients treated by HCPs received treatment in the community (e.g., from a paramedic or medical practitioner) or in hospital. Double dagger (‡) Assumed because no data were identified

Cost Inputs {#Sec5}
-----------

Costs for ambulance and hospitalization were taken from a study estimating the costs associated with emergency care and hospitalization for severe hypoglycemia in Italy \[[@CR15]\]; hospitalization is a weighted average reimbursed cost per hospitalized patient with diabetes that is based on Diagnosis Related Group reimbursement methodology. Costs for A&E and GP visits were taken from a cost analysis of the HYPOS-1 study \[[@CR12]\]. The cost of a diabetes specialist visit was obtained from a study of the cost of management of severe hypoglycemia in Italy \[[@CR15]\] and is in line with the cost of visits to other medical specialists published in Italian national tariffs \[[@CR16]\]. The cost of an extra SMBG test was taken from a study of the cost-effectiveness of SMBG in patients with T2DM in France, Germany, Italy, and Spain \[[@CR17]\] and was inflated to 2017 Euros using health price indices for Italy \[[@CR18]\]. Cost inputs are shown in Table [2](#Tab2){ref-type="table"}.Table 2Minimum and maximum cost of a hypoglycemic episode for type 1 diabetes mellitus and type 2 diabetes mellitus in ItalyResourceCost inputs (unit cost \[reference\])Minimum cost of episodeMaximum cost of episodeAmbulance€205.00 \[[@CR15]\]--€205.00A&E€241.00 \[[@CR12]\]--€241.00Hospitalization€5317.00 \[[@CR15]\]--€5317.00GP visit€25.82 \[[@CR12]\]----Diabetes specialist visit€23.00 \[[@CR15]\]--€23.00Extra SMBG tests€0.82 \[[@CR17], [@CR18]\]€4.59€4.59Totaln/a€4.59€5790.59*A&E* Accident and emergency, *GP* general practitioner, *n/a* not applicable, *SMBG* self-monitoring of blood glucose

Sensitivity Analyses {#Sec6}
--------------------

Severe and non-severe hypoglycemia rates were varied by ± 10--50%, both separately and in combination, to explore the potential cost saving/increase associated with a reduction/increase in hypoglycemia rates. All model inputs were also varied by ± 20% to assess the level of uncertainty. Finally, the diabetes prevalence was varied in order to further explore the impact of hypoglycemia on the Italian healthcare system.

This article does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec7}
=======

The LIHT highlights the cost burden of hypoglycemia in Italy for insulin-treated adults with diabetes. The direct cost of a hypoglycemic episode ranges from €4.59 to €5,790.59, where the minimum cost corresponds to a non-severe episode for which the only cost incurred is additional SMBG testing and the maximum cost is for a severe episode that is treated in hospital and requires an ambulance, the A&E service, and a diabetes specialist (Table [2](#Tab2){ref-type="table"}). The variation in cost per hypoglycemic episode arises due to differences in healthcare resource use for individual patients. The estimated average cost of a severe episode is €683.14 for T2DM and €129.77 for T1DM, while the average cost of a non-severe episode is €4.59 for both T1DM and T2DM. A breakdown of average costs by healthcare resource is shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Cost breakdown by resource for an average severe and non-severe hypoglycemic episode. Hospital costs is the cost of A&E and hospitalization; HCP consultations is the cost of GP and diabetes specialist visits. *HCP* healthcare professional

The total direct cost of insulin-related hypoglycemia in Italy is estimated to be €144.7 million per year, of which €65 million is attributable to severe episodes and €79.6 million is attributable to non-severe episodes. The total cost for a hypothetical general population of 100,000 people was also calculated to facilitate the assessment of cost burden in a specific region or hospital; this is estimated to be €238,843, with €107,370 and €131,473 due to severe and non-severe episodes, respectively (Table [3](#Tab3){ref-type="table"}). The total cost of hypoglycemia associated with T2DM is approximately €91.7 million, 1.7-fold higher than the cost associated with T1DM (€53 million; Table [3](#Tab3){ref-type="table"}). This difference can be largely attributed to the approximately five-fold higher total cost of treating severe episodes in patients with T2DM than in those with T1DM (approximately €54.1 million vs. €10.9 million), which is incurred despite patients with T2DM experiencing fewer severe episodes per year (79,218 vs. 84,196 for those with T1DM).Table 3Cost of insulin-related hypoglycemia in ItalyPopulation (*n*)Severity of episodeTotalSevereNon-severeItalian general population (60,579,000) T1DM (171,828)€10,926,180€42,055,522€52,981,702 T2DM (2,924,258, of whom 880,202 are receiving insulin)€54,117,474€37,589,540€91,707,014 Total€65,043,654€79,645,062€144,688,715Sample general population (100,000) T1DM (284)€18,036€69,423€87,459 T2DM (4827, of whom 1453 are receiving insulin)€89,334€62,050€151,384 Total€107,370€131,473€238,843*n* number of patients, *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus

A reduction in hypoglycemia may be achieved, for example, by switching a patient's current insulin treatment to an insulin with a better hypoglycemic profile. To explore the potential variation in budget impact arising from differences in hypoglycemia event rate, the rates of severe and non-severe episodes were varied by ± 10--50%, both separately in a one-way sensitivity analysis (Electronic Supplementary Material \[ESM\] Table 1) and in combination in a two-way sensitivity analysis (ESM Table 2). The results show that reductions in the rates of hypoglycemia events result in substantial cost savings. For example, in a sample general population of 100,000, a 30% reduction leads to an annual cost saving of €32,211 for severe episodes, €39,442 for non-severe episodes and €71,653 for both severe and non-severe episodes combined.

To assess the uncertainty surrounding the model inputs, we performed one-way sensitivity analyses in which all unit costs and utilization values were varied by ± 20%. The most influential variables were associated with treatment setting for patients with T2DM (percentage of patients treated by HCPs and percentage of patients hospitalized for a severe episode) and with additional SMBG testing after non-severe episodes. The main drivers of the model are shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Tornado diagram showing the main drivers of the model for a sample general population of 100,000. *A&E* accident and emergency, *HCP* healthcare professional, *SMBG* self-monitoring of blood glucose, *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus

ISTAT data for 2016 show that the overall prevalence of diabetes in Italy varies between regions, ranging from 3.2% in the Autonomous Province of Trento in the north, to 7.9% in the southern region of Calabria \[[@CR19]\]. A sensitivity analysis exploring the impact of diabetes prevalence on the cost of insulin-related hypoglycemia was therefore also performed (ESM Table 3). A disease prevalence of 8.0% in a sample general population of 100,000 is associated with a total cost of €313,932, which is an increase of €75,089 compared with the default model prevalence of 6.1%. A prevalence of 3.0% is associated with a cost of €117,724 (reduction of €121,119 versus the default model).

Finally, alternative model inputs for glucose and/or glucagon utilization, and SMBG unit cost, were tested in scenario analyses (ESM Table 4). In the base case analysis the cost of glucose and/or glucagon was conservatively assumed to be zero for severe hypoglycemic episodes treated at home or work as no data on the utilization of treatment were identified. The potential impact of this assumption was investigated by applying the average utilization and costs of the UK and Danish LIHT analyses \[[@CR5], [@CR6]\]; this had a small effect on the overall results, increasing the total cost of T1DM and T2DM by €22,724 and €18,207, respectively, from the default values. Applying alternative SMBG unit costs had a larger effect on the results, with the greatest impact observed when this cost was taken from a study in patients with T2DM that used data on SMBG unit cost from two regions in northern Italy \[[@CR20]\].

Discussion {#Sec8}
==========

In this study we highlight the cost to the Italian healthcare system of insulin-related hypoglycemia in adults with diabetes. The results show that, although frequently overlooked, non-severe hypoglycemia incurs the greatest cost, with an estimated total of €79.6 million per year (55% of the total annual cost). The total cost of hypoglycemia associated with T2DM is approximately 1.7-fold higher than that associated with T1DM.

The higher average cost of a severe episode for patients with T2DM compared with that for those with T1DM likely reflects the fact that, on average, people with T2DM have a shorter duration of diabetes and are therefore less familiar with hypoglycemia and the treatment required. These individuals may be more likely than those with T1DM to require medical assistance for a severe episode instead of receiving treatment from family or friends. This, along with the association of T2DM with older age (and therefore increased frailty) and the presence of comorbidities, is likely to increase the need for hospital admission. Indeed, for patients with diabetes experiencing severe hypoglycemia, T2DM was recently found to be associated with more frequent hospitalizations and longer length of hospital stay compared with T1DM \[[@CR12]\].

In the sensitivity analyses, the proportion of patients with T2DM who received treatment from a HCP for a hypoglycemic episode, the proportion of patients with T2DM who were treated in hospital for a severe episode, and the number of extra SMBG tests used following non-severe episodes, had the largest effect on the overall results; these are therefore the inputs associated with the greatest uncertainty. Utilization of HCPs, A&E, and hospital treatment were also identified as key drivers of the model. SMBG testing and the utilization of services such as HCPs and hospitals were also key model drivers in analyses performed using the LIHT in the UK \[[@CR5]\], Denmark, \[[@CR6]\] and Spain \[[@CR7]\].

Hypoglycemia is a common adverse effect of insulin therapy and despite pharmacological and technological advances, event rates in clinical practice remain high \[[@CR21]\]. Hypoglycemia is a key barrier to the intensification of insulin therapy; physicians acknowledge that many insulin-treated patients do not have adequate glycemic control, and 70% would treat more aggressively were hypoglycemia not a concern \[[@CR22]\]. Hypoglycemia risk can be reduced by switching a patient's current insulin treatment to insulin therapy with a better hypoglycemic profile; indeed, reductions of up to 50% have been observed upon switching from neutral protamine Hagedorn (NPH) insulin to insulin analogues \[[@CR23], [@CR24]\], or from older to newer insulin analogues \[[@CR25], [@CR26]\]. However, other factors also contribute to hypoglycemia rates. In particular, structured education and training programs in self-management of diabetes are now recognized as an important strategy for minimizing hypoglycemia risk \[[@CR27]\]. The LIHT allows healthcare decision-makers to explore how introducing new insulin therapies or self-management programs could impact healthcare budgets by enabling them to balance these costs with the savings that can be realized when hypoglycemia rates are reduced. In the current study, sensitivity analyses exploring the impact of varying hypoglycemia rates show that reductions in severe and non-severe events result in substantial cost savings.

The costs of hypoglycemia in Italy are unlikely to be overestimated in this study because of several conservative assumptions. Firstly, only an adult, insulin-treated population is considered in the model. There are far fewer children than adults with diabetes in Italy, and it is difficult to speculate about the cost of hypoglycemia in these patients compared with adults. However, there will inevitably be additional costs of treating hypoglycemia for the 21,000 children aged 0--14 years with diabetes in Italy \[[@CR1]\]. The model also only considers insulin-related hypoglycemia; however, while hypoglycemia is most commonly associated with insulin treatment, it is also a complication of other glucose-lowering medications, such as sulfonylureas and glinides \[[@CR28]\].

Secondly, the hypoglycemia rates used in the analysis are likely to be conservative. Rates of severe and non-severe hypoglycemia were taken from HYPOS-1 \[[@CR10]--[@CR12]\], a retrospective, questionnaire-based study that relied on patient recall. Hypoglycemic episodes are frequently under-reported by patients in real-world practice; indeed, a study of insulin-treated diabetes across seven European countries found that 65% of patients with T1DM and 50--59% of patients with T2DM rarely or never inform their GP or diabetes specialist about non-severe hypoglycemic events \[[@CR29]\]. Patients may be reluctant to report hypoglycemia for several reasons, including implications for employment, the risk of losing their driving license, and the fear that they will be perceived to have poor disease control. The model also does not account for asymptomatic hypoglycemia, an aspect of diabetes associated with impaired awareness of hypoglycemia. Approximately 50% of patients with T1DM \[[@CR29], [@CR30]\] and 45% with T2DM \[[@CR29], [@CR31]\] were reported to experience impaired awareness of hypoglycemia in questionnaire-based studies.

Thirdly, indirect costs incurred when absence from work due to hypoglycemia results in lost productivity are not considered in the model, as they do not directly affect the clinician or budget holder. The financial impact on the patient and their family and friends is therefore an additional cost to society that is not accounted for in the current study.

Finally, while hypoglycemia is an acute complication of diabetes, it may also impose a long-term cost burden, for example when fear of hypoglycemia leads patients to reduce or omit an insulin dose, leading to sub-optimal glucose control and increased risk of long-term complications \[[@CR32], [@CR33]\]. Such long-term cost implications of hypoglycemia are not considered in the current analysis.

There are some limitations associated with the LIHT analysis due to a lack of resource utilization data for Italy. Firstly, data on the percentages of severe episodes treated in different settings (by family and friends at home/work or by HCPs in the community/hospital) were taken from a survey of people with severe hypoglycemia in Germany, Spain, and the UK \[[@CR13]\]. Secondly, due to a lack of utilization data, glucose and/or glucagon costs are conservatively assumed to be zero for non-severe episodes and for severe episodes treated at home/work. When tested in a scenario analysis by applying the average utilization and costs from the UK and Danish LIHT analyses \[[@CR5], [@CR6]\], this assumption was found to have only a small impact on the overall results. For severe episodes treated in the community/hospital, glucose and/or glucagon costs are assumed to be included in the cost of ambulance, A&E, or hospitalization tariff to avoid double counting. Finally, as Italian data on the number of extra SMBG tests used following hypoglycemic episodes were not available, a survey of patients with diabetes experiencing non-severe episodes in the US, UK, Germany, and France \[[@CR14]\] was used. The values for non-severe episodes are assumed to also apply to severe episodes, a conservative assumption given that patients are likely to monitor their blood glucose levels more frequently following a severe episode than a non-severe episode. Given the potential for regional variation in SMBG unit costs in Italy \[[@CR34]\], and the observed impact of extra SMBG testing in sensitivity analyses, alternative costs of SMBG testing were also explored in scenario analyses. The greatest impact on the results was seen when the SMBG unit cost reported by Afonso et al. \[[@CR20]\] was applied; this study was not selected for the base case analysis as the SMBG unit cost reflects two northern Italian regions only.

Conclusions {#Sec9}
===========

This study highlights the substantial economic burden of insulin-related hypoglycemia for adults with diabetes in Italy. The LIHT is a useful model for estimating the costs of severe and non-severe hypoglycemic episodes for Italy as a whole, as well as for individual regions or hospitals. The tool may also aid healthcare decision-makers in their treatment choices by allowing the costs of insulin therapies or diabetes self-management programs to be balanced with the savings provided by reductions in hypoglycemia rates.
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